Cancer

Sonnet BioTherapeutics Announces a Publication Demonstrating Safety and Tolerability of SON-1010 in Healthy Volunteers

PRINCETON, NJ / ACCESSWIRE / February 29, 2024 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a clinical-stage company developing targeted immunotherapeutic…

2 years ago

Kidney Foundation Marks 60th Anniversary

Learn more during Kidney Health Month in MarchMontreal, Quebec--(Newsfile Corp. - February 29, 2024) - When the Kidney Foundation of…

2 years ago

Powerhouses QCCA and NCCA Merge to Create a Transformative New Entity in Independent Practice Oncology and Cancer Care: ONCare Alliance, LLC

After years of successful collaboration, the esteemed organizations National Cancer Care Alliance (NCCA) and Quality Clinical Cancer Associates (QCCA) have…

2 years ago

Cosmos Health Successfully Completes Acquisition of Pharmatrade’s Assets; Expects to Increase FY 2024 Annual Revenue by over $5 Million

CHICAGO, IL / ACCESSWIRE / February 29, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified,…

2 years ago

AIM ImmunoTech Outlines Recent Progress Across Clinical Development Pipeline and Provides Business Update

Company continues progress across Ampligen® clinical development programs Growing body of promising data demonstrates Ampligen’s potential to address multiple high-value…

2 years ago

SpringWorks Therapeutics Announces European Medicines Agency Validation for Marketing Authorization Application of Nirogacestat for the Treatment of Adults with Desmoid Tumors

Application based on Phase 3 DeFi trial in which nirogacestat significantly improved progression-free survival and objective response rate compared to…

2 years ago

Independent Lab Confirms Immunogenicity and Protection with IMUNON’s IMNN-101 in a Live Virus Challenge Against SARS-CoV-2 Variant XBB.1.5

Murine Study by the Wistar Institute Builds Upon Favorable Results Previously Reported by IMUNON With its Prototype PlaCCine Vaccine Modality…

2 years ago

CytoDyn Announces FDA Has Lifted Clinical Hold

Webcast to Provide Company Update on March 5, 2024 VANCOUVER, Washington, Feb. 29, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB:…

2 years ago

Autonomix Signs Key Clinical Agreements in Preparation to Begin March 2024 Human Clinical Trial

Proof-of-concept (PoC) human clinical trial targeting multi-billion-dollar pancreatic cancer market through transvascular RF ablation Agreements represent final steps needed in…

2 years ago

Kineta Announces Restructuring and Exploration of Strategic Alternatives

SEATTLE, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of…

2 years ago